GlassScriptPhysician profile
Irina Daniel
NPI 1831399583
$5,951.68
in general payments reported to CMS, 2019-2025
29 companies · $20.20 in 2025
The $20.20 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,497 · 2020: $50.12 · 2021: $312 · 2022: $801 · 2023: $1,868 · 2024: $1,404 · 2025: $20.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,292.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,251.55 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $703.08 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $616.69 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $534.22 | 2019-2024 | |
| Glaxosmithkline, LLC. | $461.05 | 2019-2024 | Shingrix, Arexvy |
| Abbvie INC. | $439.94 | 2019-2024 | Linzess, Viberzi, Creon |
| Ardelyx, INC. | $236.07 | 2023-2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $163.32 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Mannkind Corporation | $153.33 | 2022-2023 | Afrezza |
| Novartis Pharmaceuticals Corporation | $146.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.02 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $141.09 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.76 | 2019-2024 | Xifaxan |
| Sanofi Pasteur INC. | $120.55 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.99 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $101.26 | 2019 | |
| Sumitomo Pharma America, INC. | $93.07 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $85.08 | 2019-2023 | Veozah, Myrbetriq |
| Sunovion Pharmaceuticals INC. | $63.43 | 2019 | |
| Alexion Pharmaceuticals, INC. | $49.86 | 2019 | |
| Exact Sciences Corporation | $49.09 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $26.70 | 2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $21.27 | 2019 | |
| Livanova USA, INC. | $19.47 | 2019 | |
| Corium, LLC | $18.92 | 2023 | Adlarity |
| Lilly USA, LLC | $17.76 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.28 | 2019 | |
| Coopersurgical, INC. | $15.91 | 2022 | |
| Theracosbio, LLC | $12.24 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.